These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20465620)

  • 21. Presence of human immunodeficiency virus-1-specific CD4 and CD8 cellular immune responses in children with full or partial virus suppression.
    Papasavvas E; Sandberg JK; Rutstein R; Moore EC; Mackiewicz A; Thiel B; Pistilli M; June RR; Jordan KA; Gross R; Maino VC; Nixon DF; Montaner LJ
    J Infect Dis; 2003 Sep; 188(6):873-82. PubMed ID: 12964119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between human T lymphotropic virus (HTLV) type 1/2 viral burden and clinical and treatment parameters among patients with HIV type 1 and HTLV-1/2 coinfection.
    Beilke MA; Traina-Dorge VL; Sirois M; Bhuiyan A; Murphy EL; Walls JM; Fagan R; Winsor EL; Kissinger PJ
    Clin Infect Dis; 2007 May; 44(9):1229-34. PubMed ID: 17407044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection.
    Lascar RM; Lopes AR; Gilson RJ; Dunn C; Johnstone R; Copas A; Reignat S; Webster G; Bertoletti A; Maini MK
    J Infect Dis; 2005 Apr; 191(7):1169-79. PubMed ID: 15747254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
    Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
    Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
    Zhang ZN; Shang H; Jiang YJ; Liu J; Dai D; Diao YY; Geng WQ; Jin X; Wang YN
    Chin Med J (Engl); 2006 Dec; 119(23):1966-71. PubMed ID: 17199940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
    Smit MC; Haverkamp MH; Weersink AJ; Boucher CA; Hoepelman IM
    Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2330-4. PubMed ID: 15587052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years.
    Cuzin L; Delpierre C; Gerard S; Massip P; Marchou B
    Clin Infect Dis; 2007 Sep; 45(5):654-7. PubMed ID: 17683004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy.
    Haslett PA; Nixon DF; Shen Z; Larsson M; Cox WI; Manandhar R; Donahoe SM; Kaplan G
    J Infect Dis; 2000 Apr; 181(4):1264-72. PubMed ID: 10751137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Papular follicular eruptions in human immunodeficiency virus-positive patients in South Africa.
    Budavari JM; Grayson W
    Int J Dermatol; 2007 Jul; 46(7):706-10. PubMed ID: 17614798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
    Horberg MA; Hurley LB; Klein DB; Follansbee SE; Quesenberry C; Flamm JA; Green GM; Luu T
    Arch Surg; 2006 Dec; 141(12):1238-45. PubMed ID: 17178967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fexofenadine, an H1-receptor antagonist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcyclopropenone in patients with alopecia areata.
    Katagiri K; Arakawa S; Hatano Y; Fujiwara S
    J Dermatol; 2006 Feb; 33(2):75-9. PubMed ID: 16556272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus.
    Eschler DC; Klein PA
    J Drugs Dermatol; 2010 Aug; 9(8):992-7. PubMed ID: 20684150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lichenoid drug eruption induced by colchicine: case report.
    An I; Demir V; Akdeniz S
    Cutan Ocul Toxicol; 2017 Jun; 36(2):199-200. PubMed ID: 27345420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pruritic papular eruption in HIV seropositive patients: a cutaneous marker for immunosuppression.
    Boonchai W; Laohasrisakul R; Manonukul J; Kulthanan K
    Int J Dermatol; 1999 May; 38(5):348-50. PubMed ID: 10369543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.